Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
28. Februar 2024 08:00 ET
|
Protara Therapeutics
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics to Participate in Upcoming Investor Conferences
31. Januar 2024 07:30 ET
|
Protara Therapeutics
NEW YORK, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology
30. November 2023 08:30 ET
|
Protara Therapeutics
New results from six patients with HGTa papillary tumors show five of six patients with HGRFS at Week 12Data continue to support favorable tolerability of TARA-002 in patients with NMIBCAs previously...
Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
03. November 2023 08:00 ET
|
Protara Therapeutics
Dosing is progressing well in ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preliminary results expected in 1H24Company initiated ADVANCED-2 trial evaluating TARA-002 in NMIBC...
Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
23. Oktober 2023 08:00 ET
|
Protara Therapeutics
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ
20. September 2023 08:30 ET
|
Protara Therapeutics
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
05. September 2023 07:30 ET
|
Protara Therapeutics
NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update
03. August 2023 08:00 ET
|
Protara Therapeutics
Dosing is progressing on schedule in ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preliminary results expected in 1H24Company plans to commence dosing in ADVANCED-2 trial...
Protara Therapeutics Announces Dosing of First Patients in Phase 1b ADVANCED-1EXP Trial of TARA-002 in NMIBC Patients with Carcinoma in Situ
15. Mai 2023 08:00 ET
|
Protara Therapeutics
Dosing of first patients follows recent presentation of positive preliminary data from Phase 1a dose escalation portion of ADVANCED-1 trialCompany advancing NMIBC clinical development program, with...
Protara Therapeutics Announces First Quarter 2023 Financial Results and Business Update
04. Mai 2023 08:00 ET
|
Protara Therapeutics
Favorable tolerability and anti-tumor activity observed in NMIBC patients treated with TARA-002 in ADVANCED-1 trialCompany plans to initiate ADVANCED-2 trial in BCG-naïve CIS patients and...